Centrus Energy Corp. (LEU): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/LEU

Headline

Field	Value
Ticker	LEU
Company	Centrus Energy Corp.
Current price	$159.05/sh
Composition	Separative work units (SWU) 67% / Uranium 11% / Technical Solutions 23%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Must persist for	17.5y
Multiple paid	94x operating income

Solve inputs: computed at a 12.5% cost of capital; growth searched up to the 29.2% self-funding ceiling; each 1pp moves the implied horizon ~2 years.

Reconcile: at the x-ray's 9.3% required return this reads ~11.7 years; the models below use their own rates.

How unusual the bet is: high

Reference	Value
vs own history	+0.68σ
cohort percentile (of 80 peers)	99
sustained it ~10 years at this level	8%
implied end-window share	0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	5.69x	4	expensive
Earnings	5.35x	3	expensive
Relative	3.74x	3	expensive
Growth	1.83x	1	expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.0%); the inversion above states its own rate.

Per-Model Detail (n=11)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$0.00	—	no	Negative/zero FCF — equity value floored at $0
DCF Exit Multiple	Growth	$0.00	—	no	Negative/zero FCF or EBITDA — equity value floored at $0
Relative Valuation	Relative	$66.56	2.39x	yes	P/E 27.47x (blended: static sector reference 14x + trailing (TTM) 59x), scenarios: 20.6x / 27.5x / 33.0x (bear / base = reference held flat / bull), EV/EBITDA 17.6x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$29.19	5.45x	yes	BV/sh $34.54, ROE (TTM) 7.8%, ke 9.3%
Two-Stage Excess Return	Asset	$26.78	5.94x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$87.11	1.83x	yes	Rev $0.5B, growth 3% (input: historical growth; tapered), Terminal P/S: 4.5x / 6.0x / 7.2x (bear / base = today's held flat / bull, cap 6x)
Growth-Adjusted P/E	Relative	—	—	no	—
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$59.51	2.67x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.06B × (1−20%) / WACC 7.0% → EPV (no growth)
Residual Income	Asset	$26.40	6.02x	yes	BV $34.54 + 5yr PV of (ROE (TTM) 7.8% − Kₑ 9.3%) × BV; BV grows 5.1%/yr
Graham Number	Asset	$46.23	3.44x	yes	√(22.5 × EPS $2.75 × BVPS $34.54) — Graham's conservative floor
EV/EBITDA Relative	Relative	$42.49	3.74x	yes	EBITDA $0.03B × sector EV/EBITDA 8.0x
FCF Yield	Earnings	—	—	no	—
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	$9.84	16.16x	yes	EPS $2.75 × (8.5 + 2×-2.1%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$3.79	41.97x	yes	BV $34.54 × (ROIC 0.8% / WACC 7.0%) (excluded from median)
P/Sales Sector	Relative	$30.23	5.26x	yes	Revenue $0.45B × sector P/S 1.5x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	$29.73	5.35x	yes	EPS $2.75 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$692.1m
Net debt / NOPAT (after-tax)	-28.36x (net cash)
Net debt / operating income (pre-tax)	-22.69x (net cash)
Interest coverage	2.3x
Share count CAGR (dilution)	11.5%
Burning cash	yes

Bullet Takeaways

• Centrus enriches uranium, and its defining bet is HALEU, the high-assay low-enriched fuel that next-generation reactors need and that almost no Western company can currently make at scale.
• The price is paying for a future, not a present: at roughly 94 times operating income, today's earnings are a sliver of what the valuation assumes, and the company funds its buildout partly by issuing stock, with the share count up about 11% a year.
• The decisive catalysts are government-backed: a roughly $900 million Department of Energy HALEU task order and a $560 million centrifuge-plant expansion are the milestones that have to convert into commercial production.

Bull Case

Centrus has to be read as an early-stage industrial bet wearing the income statement of an established company, and the bull case lives in that gap. The current revenue and profit come from a legacy uranium and separative-work business plus technical-solutions contracts, but the value the market is paying for is the standing-up of domestic HALEU enrichment. The company describes its own work as "domestic centrifuge manufacturing to support commercial LEU enrichment activities at our Piketon, Ohio, facility" and its ability to deploy "LEU and/or HALEU enrichment" at scale. The trailing numbers are not the story; the buildout is. Reading Centrus on a normal earnings multiple misses what the equity is actually for.

The strategic position is genuinely scarce. HALEU is the fuel that advanced reactors require, and after decades of relying on foreign enrichment, the United States has a national-security interest in a domestic source. Centrus is the furthest-along Western company on this path, and the government is backing it with real money: a roughly $900 million Department of Energy task order to expand the Piketon facility for commercial-scale HALEU, with potential to exceed $1 billion, plus the company's own $560 million investment in its Oak Ridge centrifuge plant. The company has already contractually produced more than 1.6 metric tons of HALEU for the government, so this is not a paper plan; it is a program in execution.

The balance sheet can fund the wait. Centrus holds about $1.87 billion of cash against roughly $1.21 billion of debt, a net-cash position that, combined with government task orders, lets it build capacity without depending entirely on the equity market. It returned to profitability in the quarter, earning $10 million on $76.7 million of revenue, and raised full-year revenue guidance to $450 to $500 million. The bull case is a first-mover in a strategically essential fuel, backed by the U.S. government, with the cash to build the capacity the price is paying for.

Bear Case

The variable with the most leverage over Centrus is policy, and policy is exactly what a shareholder cannot control. The entire HALEU thesis rests on continued government funding, on advanced reactors actually getting built and needing the fuel, and on regulatory and licensing timelines that have historically slipped in the nuclear industry. The company's own framing flags the risk in the dependence: its ability to deploy enrichment hinges on "the timing, sequencing, and sc"ale of programs that are tied to federal appropriations and reactor-developer demand. A change in administration priorities, a budget squeeze, or a delay in the reactor buildout would remove the demand the price is paying for, and there is no commercial HALEU market of meaningful size today to fall back on.

The valuation makes that policy risk acute. At about 94 times operating income, no valuation family reaches the current price: it is rich on assets, on earnings power, on peer multiples, and even on forward growth. When every method sits far below the price, the market is paying for an outcome beyond what any standard frame supports, which is the definition of a bet on the optionality rather than the business. The implied assumption is roughly a decade of growth held at the self-funding ceiling, a long persistence for a company whose revenue is still under $100 million a quarter.

The funding model is the third pressure. Centrus is burning cash to build capacity, and it funds that partly by issuing equity, with the share count rising about 11% a year. That dilution is the cost of the buildout: every year of construction spreads the eventual payoff across more shares. The net-cash balance sheet is a real cushion, but the combination of a sky-high multiple, heavy dilution, and total dependence on government programs means the downside is severe if the HALEU timeline disappoints. The bear is not that the technology fails; it is that the price has already credited a commercial-scale outcome that is years away and contingent on forces outside the company entirely.

Valuation

Centrus is priced as a buildout, not a business, and the multiple makes that explicit. At today's quote the shares trade around 94 times company-wide operating income, which inverts to an assumption that operating profit grows at its self-funding ceiling for roughly thirteen years. For a company with quarterly revenue still under $100 million, that is a long and demanding runway, and it tells you the price is paying for the HALEU capacity to be built and to ramp, not for the trailing earnings.

The methods are unanimous and unhelpful: no valuation family reaches the price. The asset-value methods sit far below it. The earnings-power methods, working off a thin trailing profit, land well under. The peer-multiple lens against the nuclear-fuel cohort reaches a fraction of the price. Even the forward-growth methods, which credit aggressive expansion, fall short. When every family including the growth read is below the price, the market is not paying for one conservative method to be wrong; it is paying for an outcome beyond what any standard frame can capture, which here is the commercialization of domestic HALEU enrichment. The spread between the methods and the price is the size of that optionality bet, and it is enormous.

Solvency is the one genuinely supportive element, and it bounds the downside more than the income statement does. Centrus holds about $1.87 billion of cash against roughly $1.21 billion of debt, a net-cash position that, with the government task orders, funds the capacity buildout. The company is still burning cash to build, and it issues equity to help fund that, so the share count is rising about 11% a year, which dilutes the eventual payoff. The honest read is that the downside is bounded by the cash on hand and the government backing, while the upside is bounded only by whether HALEU demand materializes on the timeline the price assumes. This is an optionality valuation, and the methods exist here to show how far past conventional support the price sits.

Catalysts

The HALEU program drove the quarter and the outlook. On January 5, 2026, the Department of Energy announced a roughly $900 million task order to a Centrus subsidiary under its HALEU Production Contract, calling for the company to expand its Piketon, Ohio enrichment facility for commercial-scale HALEU, with potential to exceed $1 billion pending final negotiations. Centrus said it has contractually produced more than 1.6 metric tons of HALEU for the government, and in late January launched a $560 million investment in its Oak Ridge centrifuge manufacturing plant.

The financial results were modest against that ambition. Centrus earned $10 million on revenue of $76.7 million, up 5% year over year, and held about $1.87 billion of cash against $1.21 billion of debt. Management raised full-year 2026 revenue guidance to $450 million to $500 million from a prior $425 million to $475 million, and said it had identified about $300 million in potential cost savings and timing improvements since late January.

The catalysts that matter are the ones that turn the program into commercial production: final negotiation of the DOE task order, progress on the Piketon expansion and Oak Ridge centrifuge plant, and the broader pace of advanced-reactor deployment that creates demand for HALEU. Each is government- or policy-linked, which is why the stock can move sharply on funding and contract news; the cleanest reads are task-order milestones and production volumes rather than the quarterly income statement.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• CCJ (Cameco Corp)
• FY2025 40-F: …in Rule 12b-2 of the Exchange Act. Emerging growth company ☐ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting…
• FY2025 40-F: …99.8 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 99.9 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 99.10 Consent of Alain D. Renaud, P. Geo. 99.11 Consent of Biman Bharadwaj, P. Eng. 99.12 Consent of Scott…
• UEC (Uranium Energy Corp)
• FY2025 10-K: …with uranium, they are transported by truck to our Hobson Processing Facility and transferred to a tank for flushing with a brine solution, or elution, which strips the uranium from the resin beads. The stripped resin beads are then transported back to the mine and reused in the ion exchange columns. The uranium…
• FY2025 10-K: …Ltd Laramide Resources Ltd. Skyharbour Resources Ltd. Bannerman Energy Ltd enCore Energy Corp. Lotus Resources Limited Sprott Physical Uranium Trust Boss Energy Limited Energy Fuels Inc. Mega Uranium Ltd. Sprott Uranium Miners ETF Cameco Corporation F3 Uranium Corp. National Atomic Company Kazatomprom JSC Ur-Energy…
• UUUU (Energy Fuels Inc)
• FY2025 10-K: …to process other uranium-bearing materials known as Alternate Feed Materials pursuant to an Alternate Feed Guidance published by the NRC. Alternate Feed Materials are uranium-bearing materials, other than natural or native ore, usually classified as waste products by the generators of the materials, which can be…
• FY2025 10-K: …or in excess of insurance coverage, or compliance with applicable laws and regulations may cause substantial delays and require significant capital outlays, adversely affecting our future earnings and competitive position and, potentially, our financial viability. The Mill has historically been run on a campaign…
• NXE (NexGen Energy Ltd)
• (no filing in the citation store)
• BWXT (BWX Technologies Inc)
• FY2025 10-K: …from operations or by raising additional capital through debt, equity or some combination thereof. Government Operations Through this segment, we engineer, design and manufacture precision naval nuclear components, reactors and nuclear fuel for the U.S. Department of Energy ("DOE")/National Nuclear Security…
• FY2025 10-K: …segment also provides various other services, primarily through joint ventures, to the U.S. Government including nuclear materials management and operation, environmental management and administrative and operating services for various U.S. Government-owned facilities. These services are provided to the U.S.…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Centrus Q1 2026 results, May 2026 · Centrus Q1 2026 earnings call, May 2026